Ministry of Health and Welfare Releases Draft Amendments to Pharmaceutical Industry Act
Statute of Limitations Introduced for Rebates... Administrative Actions Older Than 5 Years Excluded from Review
New Certification Track for Foreign Companies

The government is revamping the certification system for innovative pharmaceutical companies to transform the domestic pharmaceutical and bio industry into an ecosystem centered on "innovative drug development." The plan is to strengthen the substance of the system by raising the research and development (R&D) investment criteria and to promote global open innovation by introducing a customized certification track for foreign companies.


Certification Bar Raised for "Innovative Pharmaceutical Companies"... R&D Ratio Increased to 7-9% View original image

On March 26, the Ministry of Health and Welfare announced that it would be releasing for public consultation the revised enforcement decree, enforcement rules, and related notifications for the "Special Act on Fostering and Supporting the Pharmaceutical Industry," which include these changes.


First, the proportion of R&D investment to pharmaceutical sales, which is a requirement for the certification of innovative pharmaceutical companies, will be raised. For companies with sales of 100 billion won or more, the required R&D investment ratio will increase from 5% to 7%. For companies with sales below 100 billion won, the ratio will go up from 7% to 9%, an increase of 2 percentage points in each case. Companies that meet international quality standards such as cGMP (Current Good Manufacturing Practice) or EU GMP will also see the required ratio increase from 3% to 5%.


The Ministry of Health and Welfare explained, "Since the introduction of the system in 2012, the increase in the R&D investment ratio for innovative pharmaceutical companies (3 percentage points) has been greater than that for general listed companies (1.4 percentage points)." The ministry added, "However, considering the preparation period needed by companies, the revised sales-based ratio requirements will be implemented after a three-year grace period following promulgation."



The revision also includes the division of certification types into "general innovative" and "foreign innovative" categories to strengthen cooperation with global pharmaceutical firms, with detailed review standards differing for each category. This measure reflects the unique characteristics of foreign companies, which have differed from the domestic R&D environment.



For the certification of foreign innovative pharmaceutical companies, the scoring for attracting domestic research centers, joint research, and technology transfer will be significantly increased. In contrast, the scores for candidate substance development and patent technology transfer activities carried out primarily by headquarters will be lowered, in order to encourage the active inflow of global capital and technology into the domestic ecosystem.


The criteria for canceling certification related to rebates, which have increased management uncertainty for companies, will also be rationalized. Previously, certification could be immediately revoked based on litigation results, even for violations that occurred long ago. Going forward, any violations that ended more than five years prior to the date of review will be excluded from the certification or renewal review process.


In addition, the detailed evaluation criteria for the certification review of innovative pharmaceutical companies will be fully disclosed in the notification, and the number of review items will be streamlined from 25 to 17. Key indicators such as R&D investment and the number of clinical trials will be quantified to enhance objectivity in evaluation, and a new item will be established to assess excellence in social responsibility activities, such as pharmaceutical production and distribution, that contribute to supply chain stabilization. The minimum passing score for certification (65 points) will be specified in the notification, and for companies that fail to be certified, the reasons for non-certification will be stated and communicated to them, thereby improving the transparency of the certification process.



The Ministry of Health and Welfare plans to finalize the revision after collecting public feedback by May 6. A ministry official stated, "Taking this pharmaceutical pricing system improvement as an opportunity, we plan to systematically analyze the types and capabilities of domestic pharmaceutical and bio companies and establish a 'National Pharmaceutical and Bio Industry Development Strategy' within this year."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing